Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Release Date: August 26, 2025

Expiration Date: August 26, 2026

Activity Overview

Immunotherapy-based approaches have fundamentally transformed the management of unresectable hepatocellular carcinoma (HCC). However, questions related to appropriate patient selection, therapy sequencing, and the role of immunotherapy in the non-advanced disease settings have remained unanswered. In this program, expert faculty in the management of HCC provide recent updates on the use of established immunotherapy-based treatment approaches for HCC, with an emphasis on the treatment of patients who have traditionally fallen outside the inclusion criteria of pivotal clinical trials.

Target Audience

This educational activity is directed toward US-based medical oncologists, gastrointestinal (GI) oncologists, advanced practice providers, nurses, and other health care professionals who treat patients with GI cancers.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate immune-based treatment strategies for advanced hepatobiliary cancers and their applicability to diverse patient populations, including those with hepatic dysfunction or poor performance status.
• Apply recent evidence to inform treatment selection, sequencing, and delivery of immunotherapy in hepatocellular and biliary tract cancers across frontline and emerging therapeutic settings.